Search hospitals > Wisconsin > Milwaukee
Aurora Sinai Medical Center
Claim this profileMilwaukee, Wisconsin 53233
Global Leader in Parotid Gland Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Cervical Adenocarcinoma
Conducts research for Breast cancer
223 reported clinical trials
21 medical researchers
Summary
Aurora Sinai Medical Center is a medical facility located in Milwaukee, Wisconsin. This center is recognized for care of Parotid Gland Cancer, Breast Cancer, Lung Cancer, Cervical Adenocarcinoma, Breast cancer and other specialties. Aurora Sinai Medical Center is involved with conducting 223 clinical trials across 330 conditions. There are 21 research doctors associated with this hospital, such as Thomas J. Saphner, Rubina Qamar, Antony Ruggeri, and Sigrun Hallmeyer, MD.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
Top PIs
Thomas J. SaphnerAurora Saint Luke's Medical Center1 year of reported clinical research
Expert in Parotid Gland Cancer
Studies Breast Cancer
30 reported clinical trials
68 drugs studied
Rubina QamarAurora Saint Luke's Medical Center4 years of reported clinical research
Studies Parotid Gland Cancer
Studies Lung Cancer
24 reported clinical trials
68 drugs studied
Antony RuggeriAurora Cancer Care-Milwaukee West4 years of reported clinical research
Studies Parotid Gland Cancer
Studies Colon Cancer
14 reported clinical trials
57 drugs studied
Sigrun Hallmeyer, MDAdvocate Lutheran General Hospital2 years of reported clinical research
Studies Breast Cancer
Studies Cancer
13 reported clinical trials
22 drugs studied
Clinical Trials running at Aurora Sinai Medical Center
Breast Cancer
Lung Cancer
Parotid Gland Cancer
Cancer
Bladder Cancer
Breast cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Multiple Myeloma
Bladder Carcinoma
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Aurora Sinai Medical Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.